Organization | Beijing Minhai Biotechnology Co., Ltd

Beijing Minhai Biotechnology Co., Ltd Report issue

For profit Phase 2 Phase 3

Founded: Beijing China (2004)

Status: No NME R&D (2004)

Organization Overview

First Clinical Trial

2011

NCT01451086

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Beijing Minhai Biotechnology Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (12)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

haemophilus influenzae type b conjugate vaccine (PedvaxHIB) (1 trial)

hib vaccine (1 trial)

inactivated SARS-Cov-2 vaccine (5 trials)

mcv-ac vaccine group (1 trial)

mcv-acyw135 vaccine (1 trial)

minhai-hib (1 trial)

mpv-a (1 trial)

mpv-acyw135 (1 trial)

pneumococcal 7-valent conjugate vaccine (prevnar) (1 trial)

quadrivalent groups a, c, y, and w-135 meningococcal vaccine (Menomune-A/C/Y/W-135) (1 trial)

rabies vaccine (purified chick embryo cell vaccine) (RabAvert) (2 trials)

Drugs in Phase 2 Trials (1)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Haemophilus Infections (Phase 3)

Influenza, Human (Phase 3)

Meningitis (Phase 3)

Pneumonia (Phase 3)

Postpoliomyelitis Syndrome (Phase 2)

Rabies (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial APIs: 13